retatrutide 2 month results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished MurgaSkin - #retatrutide before and

The weight loss data from this period is striking

Blood Collection Blood was collected in chilled tubes supplemented with 500 KIU/ml Aprotinin (Trasylol

Since reta appears to support better blood sugar balance in experimental models, its dual action could make it a valuable compound for researchers studying metabolic function and glucose regulation

The SURMOUNT clinical trials investigating tirzepatide for weight management have reported headaches in participants, but this remains investigational for this indication in the UK

Concurrently, GLP-1 stimulates the translocation of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) into the nucleus via the PKA/ERK signaling pathway, where Nrf2 induces transcription of genes for SOD, GPx, catalase, thioredoxin, and other antioxidant enzymes, further enhancing the cellular antioxidant defense system